FILANA THERAPEUTICS, INC. - 8-K Filing

Filana Therapeutics reported Q2 2026 financial results with $82.7M cash balance and a net loss of $8.6M. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $SAVA

Read the full article at SEC EDGAR

More Regulatory news